36
Participants
Start Date
May 13, 2019
Primary Completion Date
March 8, 2023
Study Completion Date
January 31, 2026
SHP611
Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 106 weeks.
IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN, Roma
UZ Antwerpen, Edegem
Hospital Vall d'Hebrón, Barcelona
New York University Langone Medical Center, New York
Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Universitätsklinikum Hamburg Eppendorf, Hamburg
Rare Disease Research, LLC, Atlanta
Cincinnati Children's Hospital Medical Center, Cincinnati
Hospital Universitario Cruces, Barakaldo
University of Iowa Stead Family Children's Hospital, Iowa City
Mayo Clinic - PPDS, Rochester
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Tel Aviv Sourasky Medical Center, Tel Aviv
Universitätsklinikum Tübingen, Tübingen
Childrens Hospital Colorado, Aurora
University of Utah, Salt Lake City
Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance
Hôpital Bicêtre - Paris Sud, Le Kremlin-Bicêtre
Hospital Universitario Austral - PIN, Ciudad Autónoma Buenos Aires
Hospital de Clínicas de Porto Alegre, Porto Alegre
Stollery Children's Hospital University of Alberta, Edmonton
British Columbia Children's Hospital, Vancouver
Hospital for Sick Children, Toronto
Montreal Children's Hospital, Montreal
CHU Lenval, Nice
Attikon University General Hospital, Chaïdári
Kanazawa University Hospital, Kanazawa
VU Medisch Centrum, Amsterdam
Birmingham Children's Hospital NHS Foundation Trust, Birmingham
Lead Sponsor
Takeda Development Center Americas, Inc.
INDUSTRY
Shire
INDUSTRY